Ocular Therapeutix (NASDAQ:OCUL) reported Q4 2017 earnings this Morning, coming in at ($0.44) per share, beating Wall Street’s estimates of ($0.52) per Share. Revenue for the quarter came in at $0.50 million missing the streets estimates of $0.51 million Recent Insider Trading for Ocular Therapeutix (NASDAQ:OCUL)
- On 12/12/2017 Antony C Mattessich, Insider, bought 21,000 with an average share price of $4.29 per share and the total transaction amounting to $90,090.00.
- On 12/7/2017 Donald Notman, CFO, bought 4,800 with an average share price of $4.00 per share and the total transaction amounting to $19,200.00.
- On 12/6/2017 Daniel M Bollag, Insider, bought 24,700 with an average share price of $3.93 per share and the total transaction amounting to $97,071.00.
- On 11/16/2017 Amarpreet Sawhney, Chairman, bought 19,000 with an average share price of $5.18 per share and the total transaction amounting to $98,420.00.
- On 12/15/2016 Amarpreet Sawhney, Insider, bought 45,300 with an average share price of $7.85 per share and the total transaction amounting to $355,605.00.
- On 6/9/2016 Amarpreet Sawhney, CEO, bought 10,000 with an average share price of $6.70 per share and the total transaction amounting to $67,000.00.
Recent Trading for Ocular Therapeutix (NASDAQ:OCUL) Shares of Ocular Therapeutix closed the previous trading session at 5.97 up +0.02 0.34% with 5.569399833679199 shares trading hands.